Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aska to sell Sosei emergency contraceptive in Japan

This article was originally published in Scrip

Executive Summary

Aska Pharmaceutical is to undertake the sales and marketing of Sosei's oral emergency contraceptive Norlevo (SOH-075) in Japan, its home market. The agreement will see Sosei keep responsibility for the development and registration of the levonorgestrel-only product, which should be filed in the first half of next year and stands to become the first of its type in Japan. It is used to prevent unwanted pregnancy when administered within 72 hours of unprotected intercourse. Sosei originally acquired exclusive Japanese distribution rights from originator HRA Pharma, and will receive undisclosed upfront and milestone payments and a percentage of net sales from Aska. Aska already markets several oral contraceptives and fertility drugs and has acquired an equity stake in Sosei as part of the tie-up.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025545

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel